Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954394750> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W2954394750 endingPage "v309" @default.
- W2954394750 startingPage "v309" @default.
- W2954394750 abstract "Abstract Background Previous studies demonstrated that the combination of chemotherapy with ramucirumab allows to improve the treatment results in advanced gastric cancer (GC). The one of the available options for the second line chemotherapy is combination of irinotecan with fluoropyrimidines. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of irinotecan and fluoropyrimidines with ramucirumab in metastatic GC. Methods Eligible patients had advancedmorphologicallyverifiedGC and disease progression during or within 4 months following first-line therapy. They received FOLFIRI plus ramucirumab(8 mg/kg on day 1) or XELIRI in combination with ramucirumab(8 mg/kg on days 1 and 8). The primary end point was progression-free survival (PFS). Secondary end-points were overall survival (OS), disease control rate (DCR) and safety. Results Between September 2015 and October 2018, 23 patients were enrolled. Median number of cycles was 9 (2-20). Six patients achieved a partial response (PR) for an objective response rate of 26.1%. A total of 15 (65.2%) patients had stable disease (SD) for a DCR of 91.3%. With a median follow up 8,2 months, median PFS was 7.6 months (95% CI 5.9-9.2) and the median OS was 9.5 months (95% Cl 6.74 – 12.3). Median duration of PR response was 4,5 months (2,7-5,2 +) and median duration of SD was 4,2 months (2,1-10,1+ ).The main treatment-related grade 3 or 4 adverse events were decreased neutrophil count (1/23; 4.3%), anemia (1/23; 4.3%) and diarrhea (1/23; 4.3).The most frequent adverse events of special interest (AESIs) any grade were hypertension (10/23; 43.4%), bleeding/hemorrhage (5/23; 21.7%), proteinuria (5/23; 21.7%) and venous thromboembolic events (6/23; 26%). Gastrointestinal perforationdeveloped in two patients (2/23; 8.7%). No treatment-related deaths occurred. Conclusions In our research ramucirumab with irinotecan and fluoropyrimidinesdemonstrate the high activity and a manageable safety profile in patients with pre-treated metastatic GC. Legal entity responsible for the study Besova N.S. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest." @default.
- W2954394750 created "2019-07-12" @default.
- W2954394750 creator A5013754314 @default.
- W2954394750 creator A5022911908 @default.
- W2954394750 creator A5039719227 @default.
- W2954394750 creator A5083909830 @default.
- W2954394750 date "2019-10-01" @default.
- W2954394750 modified "2023-09-28" @default.
- W2954394750 title "Clinical experience: Ramucirumab with FOLFIRI/XELIRI as a second-line for patients with metastatic gastric cancer" @default.
- W2954394750 doi "https://doi.org/10.1093/annonc/mdz247.128" @default.
- W2954394750 hasPublicationYear "2019" @default.
- W2954394750 type Work @default.
- W2954394750 sameAs 2954394750 @default.
- W2954394750 citedByCount "0" @default.
- W2954394750 crossrefType "journal-article" @default.
- W2954394750 hasAuthorship W2954394750A5013754314 @default.
- W2954394750 hasAuthorship W2954394750A5022911908 @default.
- W2954394750 hasAuthorship W2954394750A5039719227 @default.
- W2954394750 hasAuthorship W2954394750A5083909830 @default.
- W2954394750 hasBestOaLocation W29543947501 @default.
- W2954394750 hasConcept C121608353 @default.
- W2954394750 hasConcept C126322002 @default.
- W2954394750 hasConcept C143998085 @default.
- W2954394750 hasConcept C2776705615 @default.
- W2954394750 hasConcept C2779551604 @default.
- W2954394750 hasConcept C2780259306 @default.
- W2954394750 hasConcept C526805850 @default.
- W2954394750 hasConcept C71924100 @default.
- W2954394750 hasConceptScore W2954394750C121608353 @default.
- W2954394750 hasConceptScore W2954394750C126322002 @default.
- W2954394750 hasConceptScore W2954394750C143998085 @default.
- W2954394750 hasConceptScore W2954394750C2776705615 @default.
- W2954394750 hasConceptScore W2954394750C2779551604 @default.
- W2954394750 hasConceptScore W2954394750C2780259306 @default.
- W2954394750 hasConceptScore W2954394750C526805850 @default.
- W2954394750 hasConceptScore W2954394750C71924100 @default.
- W2954394750 hasLocation W29543947501 @default.
- W2954394750 hasOpenAccess W2954394750 @default.
- W2954394750 hasPrimaryLocation W29543947501 @default.
- W2954394750 hasRelatedWork W2131794175 @default.
- W2954394750 hasRelatedWork W2586568707 @default.
- W2954394750 hasRelatedWork W2802627520 @default.
- W2954394750 hasRelatedWork W2949001018 @default.
- W2954394750 hasRelatedWork W3040708616 @default.
- W2954394750 hasRelatedWork W3116695951 @default.
- W2954394750 hasRelatedWork W3172249257 @default.
- W2954394750 hasRelatedWork W4284970907 @default.
- W2954394750 hasRelatedWork W4311290262 @default.
- W2954394750 hasRelatedWork W4382811306 @default.
- W2954394750 hasVolume "30" @default.
- W2954394750 isParatext "false" @default.
- W2954394750 isRetracted "false" @default.
- W2954394750 magId "2954394750" @default.
- W2954394750 workType "article" @default.